Wiley Matthew T.
Chief Commercial Officer
Wiley Matthew T. has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Aug 12, 2026.
On the most recent filing, Wiley Matthew T. is listed as Chief Commercial Officer at Definium Therapeutics, Inc. Inside the rolling window, Wiley Matthew T. reported no open-market purchases and 1 open-market sale totaling $129K in DFTX.
Companies traded
Other insiders at DFTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$129K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Wiley Matthew T. made?
Wiley Matthew T. has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Wiley Matthew T. trade?
Wiley Matthew T. has filed SEC Form 4 disclosures for 1 company, including DFTX.
When was Wiley Matthew T.'s most recent SEC Form 4 filing?
Wiley Matthew T.'s most recent SEC Form 4 filing on Tracefour is dated Aug 12, 2026.
What is Wiley Matthew T.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Wiley Matthew T. is listed as Chief Commercial Officer.
What is Wiley Matthew T.'s total buy and sell value in the current window?
Inside the rolling retention window, Wiley Matthew T. bought $0 and sold $129K based on SEC Form 4 filings.
What was Wiley Matthew T.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,867 DFTX shares on 2026-06-25, worth $129K, per SEC Form 4 filings.